The Breast Oncology Program (Program) is comprised of 39 Program Members from 13 different UCSF departments. The Program supports and stimulates basic, clinical, and population research in breast cancer and facilitates the translation of these findings into improved cancer management and control. The Program's themes are as follows: (1) epidemiology and etiology;(2) cancer prevention, risk models, and early detection;(3) genetics and biology of cancer progression;(4) new therapeutic targets and approaches;and (5) outreach, clinical care delivery, and outcomes. Research in the Program is supported by the Bay Area Breast Cancer SPORE, eight large multi-disciplinary, multi-institutional projects that support work in one or more themes, a multi-campus University of California Office of the President sponsored ATHENA Breast Health Network integrating clinical care and research by numerous individual investigator-initiated grants. Since the last competitive renewal much effort has been dedicated towards investigator initiated therapeutic trials, innovative companion diagnostic clinical trials, testing new radiation oncology treatment delivery systems including correlative science, as well as establishing a CLIA-compliant testing laboratory and an integrative bioinformatics and IT infrastructure. The Program has become more cohesive, has a high level of interaction that has led to new grant funding with joint program and project leaders and co-investigators across disciplines. Interactions between Program members are encouraged in several discussion forums, including a weekly multidisciplinary seminar, an annual retreat, a weekly tumor board, a bi-weekly breast site study review meeting, a monthly community forum, and a patient-physician management discussion series. The Program has $22,189,900 total peer-reviewed support for the last budget year. The Program has 17% intra-programmatic and 17% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082103-15S1
Application #
8710509
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-06-01
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2013
Total Cost
$74,881
Indirect Cost
$27,186
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications